Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide

Harenberg, Job

doi:10.1002/(sici)1098-1128(199801)18:1<1::aid-med1>3.0.co;2-4

Cited by 75 publications

(27 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, when SDX was administered in vivo by the parenteral route, the global plasma anticoagulant activity was consistently lower than that measured after HPs (UFH and LMWH) given at equipotent in vitro doses 21,23. This phenomenon is attributed to the quoted higher affinity of SDX for the extensive vascular and microvascular endothelium rather than for plasma proteins, and is in line with the concept, which is well accepted for low-dose UFH and LMWHs, that HP-like compounds can be effective at cellular levels even in the absence of overt anticoagulant activity in plasma.…”

Section: Pharmacology Of Sdxmentioning

confidence: 99%

“…The active doses of SDX for venous thrombogenesis in rabbits are 20 mg/kg iv for the effective dose (ED)50, and 125 mg/kg for the ED100. Within these doses, only the Heptest was prolonged but APTT and TT were unchanged 21,23…”

Section: Pharmacology Of Sdxmentioning

confidence: 99%

“…The presence of arterial antithrombotic activity is even more important by considering that SDX is also able to effectively release lipoprotein lipase activity by any administration route. In fact, SDX reduces cholesterol blood levels and aortic accumulation in cholesterol-fed rabbits32 and increases lipoprotein catabolism23 in the liver both in normal and hyper-triglyceridemic animals. In this way, SDX displays a complex anti-atherosclerotic and antithrombotic activity that can be considered an interesting property of this compound.…”

Section: Pharmacology Of Sdxmentioning

confidence: 99%

“…Many early and small studies with SDX on atherosclerotic conditions and complications can be found in the literature over 1980–2000 21,23,57…”

Section: Clinical Applications Of Sdxmentioning

confidence: 99%

See 3 more Smart Citations

Development and use of sulodexide in vascular diseases: implications for treatment

Coccheri¹,

Mannello²

2013

DDDT

116

100

View full text Add to dashboard Cite

Sulodexide (SDX), a sulfated polysaccharide complex extracted from porcine intestinal mucosa, is a blend of two glycosaminoglycan (GAG) entities, namely a fast-moving heparin (HP) fraction and a dermatan sulfate (DS; 20%) component. The compound is unique among HP-like substances in that it is biologically active by both the parenteral and oral routes. A main feature of the agent is to undergo extensive absorption by the vascular endothelium. For this reason, in preclinical studies, SDX administered parenterally displays an antithrombotic action similar to that of HPs but associated with fewer alterations of the blood clotting mechanisms and tests, thus being much less conducive to bleeding risk than HPs. When given orally, SDX is associated with minimal changes in classic coagulation tests, but maintains a number of important effects on the structure and function of endothelial cells (EC), and the intercellular matrix. These activities include prevention or restoration of the integrity and permeability of EC, counteraction versus chemical, toxic or metabolic EC injury, regulation of EC–blood cell interactions, inhibition of microvascular inflammatory and proliferative changes, and other similar effects, thus allowing oral SDX to be considered as an endothelial-protecting agent. The best available clinical evidence of the efficacy of SDX administered orally with or without an initial parenteral phase is the following: alleviation of symptoms in chronic venous disease and especially acceleration of healing of venous leg ulcers; prevention of cardiovascular events in survivors after acute myocardial infarction; marked improvement of intermittent claudication in patients with peripheral occlusive arterial disease; and abatement of proteinuria in patients with diabetic nephropathy that may contribute to the amelioration or stabilization of kidney function. Although further clinical trials are warranted, SDX is presently widely accepted in many countries as an effective and safe long-term, endothelial-protecting drug.

show abstract

Section: Pharmacology Of Sdxmentioning

confidence: 99%

Section: Pharmacology Of Sdxmentioning

confidence: 99%

Section: Pharmacology Of Sdxmentioning

confidence: 99%

“…Many early and small studies with SDX on atherosclerotic conditions and complications can be found in the literature over 1980–2000 21,23,57…”

Section: Clinical Applications Of Sdxmentioning

confidence: 99%

See 2 more Smart Citations

Development and use of sulodexide in vascular diseases: implications for treatment

Coccheri¹,

Mannello²

2013

DDDT

116

100

View full text Add to dashboard Cite

show abstract

“…In fact, sulodexide decreases triglycerides [81], increases Apo-A1 and HDL-C levels [82] and blood viscosity [83], decreases D-dimer and fibrinogen levels [84, 85], and releases tissue plasminogen activator [86, 87]. Sulodexide has a dual effect on coagulation: antithrombin catalysis by fast moving heparin component and heparin cofactor II catalysis by dermatan sulphate component [88].…”

Section: Other Effects Of Glycosaminoglycans On Cardiorenal Physiologymentioning

confidence: 99%

Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans

Cicero¹,

Ertek²

2010

aoms

View full text Add to dashboard Cite

Despite advances in pharmacological treatment, diabetic nephropathy is still the leading cause of end-stage renal disease and an important cause of morbidity and mortality in diabetics. Glycosaminoglycans are long, unbranched mucopolysaccharides that play an important role in establishing a charge-selective barrier that restricts the passage of negatively charged molecules, such as albumin and other proteins, at the level of the glomerular basal membrane. Their loss is associated with loss of selectivity and proteinuria. Extensive preclinical evidence and some clinical trials suggest that glycosaminoglycans replacement is associated with improvement of glomerular selectivity and of proteinuria. Sulodexide could also have some other effects, potentially useful to reduce the renal damage and the cardiovascular disease associated with proteinuria, such as improvement of haemorheological and blood lipid parameters, an endothelium protective effect and anti-inflammatory action. This review will discuss the evidence supporting the potential nephroprotective effects of sulodexide and other glycosaminoglycans.

show abstract

ChemInform Abstract: Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide

Harenberg

1998

ChemInform

View full text Add to dashboard Cite

show abstract

Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide

Cited by 75 publications

References 49 publications

Development and use of sulodexide in vascular diseases: implications for treatment

Development and use of sulodexide in vascular diseases: implications for treatment

Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans

ChemInform Abstract: Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide

Contact Info

Product

Resources

About